Study of HSK31858 for non-CF bronchiectasis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a body mass index (BMI) of at least 18.
- You have been diagnosed with bronchiectasis (not due to cystic fibrosis) with symptoms like chronic cough or phlegm.
- You have had at least 2 lung infections or flare-ups in the past year.
- You are not currently having a flare-up or needing treatment for one in the last 4 weeks.
- You do not have poorly controlled high blood pressure (systolic over 180 or diastolic over 110).
- You have not used certain other study drugs or medications that affect the study drug in the past few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This study looks at different types of bronchiectasis in Chinese patients to understand the disease better. It may involve additional tests like lung function and questionnaires.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.